CTOs on the Move

Institut National de Sante Publique du Quebec

www.inspq.qc.ca

 
Our goal is to advance knowledge and propose crosssectoral strategies and endeavours that will improve the health and well-being of Québecers. The Institut national de santé publique du Québec (INSPQ) was created in 1998 following the adoption of its act of incorporation (RSQ, chapter I-13.1.1). Its experts come from fields as distinct as applied science, health sciences, social sciences, and humanities and work with the health and social services network to develop and pool public health knowledge and skills.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.inspq.qc.ca
  • 945, av Wolfe
    Quebec City, QC CAN G1V 5B3
  • Phone: 418.650.5115

Executives

Name Title Contact Details

Similar Companies

Applied Biometrics

Applied Biometrics is a Glendale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sandy Springs Fitness

Sandy Springs Fitness is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chester River Health System

Chester River Health System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Chestertown, MD. To find more information about Chester River Health System, please visit www.chesterriverhealth.org

Pacific Hospitalist Associates

Pacific Hospitalist Associates is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.